Keiko Kajitani

Keiko Kajitani

Auto-generated profile, based on publicly available information

Keiko Kajitani

Department of Healthcare Economics Tokyo Medical and Dental University Bunkyo‐ku Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Clinical Breast Cancer
Verified
Journal Article
Closed access
EAEtsushi Akimoto
Etsushi Akimoto
TKTakayuki Kadoya
Takayuki Kadoya
KKKeiko Kajitani
Keiko Kajitani
AEAkiko Emi
Akiko Emi
HSHideo Shigematsu
Hideo Shigematsu
MOMorihito Okada
Morihito Okada

16 October 2023 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
HYHiroaki Yamane
Hiroaki Yamane
TITomoko Itagaki
Tomoko Itagaki
KKKeiko Kajitani
Keiko Kajitani
YKYuji Koura
Yuji Koura
YKYoshiharu Kawabuchi
Yoshiharu Kawabuchi
MOMasahiro Ohara
Masahiro Ohara
Cystoid macular edema (CME) is a rare side effect associated with chemotherapy. Although the development of CME has been reported to occur following treatment with taxane drugs, such as nanoparticle albumin-bound paclitaxel (Nab-PTX), the occurrence of CME with treatment with atezolizumab has not yet been reported. Here, we report the case of a 49-year-old woman who developed CME 19 months into chemotherapy with Nab-PTX and atezolizumab. Improvement was not achieved with steroid injections into the Tenon’s sac, and Nab-PTX and atezolizumab treatments were ceased. One month later, there was subjective improvement in her symptoms. Although many reports have indicated that cessation of chemotherapy has successfully improved CME, a specific treatment for CME has not yet been established. Clinicians should be aware of the ophthalmologic side effects and offer immediate treatment if symptoms develop.

1 September 2019 in Journal of Radiation Oncology
Verified
Journal Article
Closed access
PDF file
YKYuri Kimura
Yuri Kimura
SSShinsuke Sasada
Shinsuke Sasada
NGNoriko Goda
Noriko Goda
KKKeiko Kajitani
Keiko Kajitani
AEAkiko Emi
Akiko Emi
MOMorihito Okada
Morihito Okada

8 November 2023 in The International Journal of Health Planning and Management
Verified
Journal Article
Open access
KKKoichi Kawabuchi
Koichi Kawabuchi
KKKeiko Kajitani
Keiko Kajitani
Financial pressure on younger generation is mounting in Japan, a super-ageing society with staggering economy. The revision on the co-insurance rate for 70-74 with "Standard" category was implemented to mitigate such pressure, seeking better balance across generations in sharing the burden of healthcare cost. It raised the rate from 10% to 20% over the period of five years from 2014 to 2018. This report examined how it changed the share of cost sharing (cost sharing as percentage to total healthcare expenditure), among the 70-74 with "Standard" category in Citizens Health Insurance programme in 44 prefectures. It specifically focused on change in the population's actual share of cost sharing (ASCS) that better reflect the genuine amount of payment actually made by the patients themselves. The average ASCS increased from 7.28% (2013) to 10.78% (2019), resulting wider gap from the statutory planned share of cost sharing (i.e., the statutory co-insurance rate of 10% in 2013, and 20% in 2019). Also found was increased variance among prefectural ASCS, which may suggest a possibility of un-designed effect by the revision, of encouraging a move towards ability and willingness to pay. In terms of cost containment effect, Japan needs to consider various non-conventional options, including review of the current use of healthcare resources. First and foremost, however, the true state of cost sharing should be recognized in terms of ASCS and shared more widely as a reality. Such effort is essential in discussion of how to keep embracing the country's life line, UHC.

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NMNorio Masumoto
Norio Masumoto
TKTakayuki Kadoya
Takayuki Kadoya
MFMakoto Fujiwara
Makoto Fujiwara
CMChika Murakami
Chika Murakami
Toru YoshikawaToru Yoshikawa
Toru Yoshikawa
MOMorihito Okada
Morihito Okada
E12097 Background: Unlike whole body (WB) 18F-fluorodeoxyglucose (FDG) PET, dedicated breast PET (DBPET) enables detailed high-resolution images within the breast and quantitative assessment using SUV. We aimed to determine whether DBPET can detect ductal carcinoma in situ (DCIS) and predict the malignancy and neoplastic progress of invasive breast cancer. Methods: We investigated 155 consecutive patients with breast cancer who underwent concurrent DB– and WB– PET (Elmammo®) between January and November 2016. All DB– and WB– PET images were quantified based on standard uptake values (SUV). We also assessed 12 patients with ring-like uptake (RU) without central FDG accumulation in invasive breast cancers on DBPET images. Results: The SUV (means ± SD) determined from DB– and WB– PET images of breast cancer were 8.2 ± 7.7 and 3.1 ± 3.3 respectively. We detected DCIS in DB- and WB– PET images from 22 (84.7%) and 15 (57.6%) of 26 among the 155 patients, respectively (p = 0.003). The SUV on WB– PET images was significantly higher for NG3 than for NG1-2 (p = 0.004), and for high (≥ 20%) than low ( < 20%) Ki67 (p = 0.003), and significantly lower for Luminal A than Luminal B, HER2 and triple-negative cancer (p < 0.05 for all three). The SUV for NG (p = 0.002), Ki67 (p = 0.001) and the luminal (p < 0.05) type also significantly differed in DBPET images. RU without central FDG accumulation was evident in DbPET images of 12 patients, all of whom had Ki67 ≥ 20 (p = 0.0001), two had NG1-2 and 10 had NG3 (p = 0.005), one had clinical T1, 11 had T2 (p = 0.0004), five had clinical N0 and seven had N1 (p = 0.03). RU was associated with high-grade malignancy and neoplastic progress. Conclusions: The detection rate of DBPET was excellent for DCIS. The RU on DBPET offers predictive value for high-grade malignancy and the neoplastic progress of invasive breast cancer. Thus, DBPET might help to determine therapeutic strategies.